Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,118 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo 40 mg Clear all
Completed Phase 2 Interventional Results available

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

NCT00942305
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Brincidofovir, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670501
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide, Placebo, Calcium Supplement, Vitamin D Supplement
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 85 Years · Female only
Enrollment
1,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2008 · Synced Oct 18, 2026, 9:51 AM EDT
Terminated Phase 3 Interventional Results available

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

NCT00257192
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, Ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
46
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

NCT00280566
View directory record Official record
Conditions
Bipolar Mania, Bipolar Disorder
Interventions
Placebo, Ziprasidone Oral Capsule
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
73
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

NCT00677053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
TAK-442, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
30 Years to 80 Years
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

NCT02570854
View directory record Official record
Conditions
Anemia, Iron-Deficiency
Interventions
CSJ137, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
San Diego, California • Lakewood, Colorado • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 18, 2026, 9:51 AM EDT
Completed No phase listed Observational

Long Term Follow Up KET-PD

NCT06164756
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
Cognitive Behavior Therapy (CBT), Treatment As Usual (TAU)
Other
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Recruiting Phase 4 Interventional

Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

NCT04166877
View directory record Official record
Conditions
Trauma, Acute Pain
Interventions
Magnesium Sulfate in Parenteral Dosage Form, Normal saline placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

NCT05165550
View directory record Official record
Conditions
HIV-1-infection
Interventions
Elsulfavirine
Drug
Lead sponsor
Viriom
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Nalmefene Smoking Cessation Study

NCT00202696
View directory record Official record
Conditions
Smoking Cessation
Interventions
nalmefene, Placebo
Drug · Other
Lead sponsor
Somaxon Pharmaceuticals
Industry
Eligibility
25 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

NCT00199420
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

NCT01086748
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Placebo, LY2140023
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Escondido, California • Garden Grove, California • Paramount, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

NCT01082640
View directory record Official record
Conditions
Renal Impairment
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

NCT05648110
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
3,882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
130
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

NCT05918627
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

NCT00644605
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
sildenafil, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

NCT01140451
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

NCT01404754
View directory record Official record
Conditions
Psychological Effects of Study Drug
Interventions
Lactose (inactive placebo), midomafetamine HCl
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
3
States / cities
Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

NCT00244751
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
GI262570 0.5 mg, GI262570 1.0 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

NCT02255422
View directory record Official record
Conditions
MItochondrial Myopathies
Interventions
Omaveloxolone capsules, 2.5 mg, omaveloxolone capsules, 5 mg, omaveloxolone capsules, 10 mg, Placebo capsules, omaveloxolone capsules, 20 mg, omaveloxolone capsules, 40 mg, omaveloxolone capsules, 80 mg, omaveloxolone capsules, 160 mg
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Boston, Massachusetts • Akron, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

NCT02106832
View directory record Official record
Conditions
Bronchiectasis
Interventions
Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Peoria, Arizona • Fountain Valley, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 18, 2026, 9:51 AM EDT
Recruiting Phase 3 Interventional

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805
View directory record Official record
Conditions
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300456
View directory record Official record
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335, Simvastatin, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 18, 2026, 9:51 AM EDT